Progress Report: Sri Lanka Clinical Trials Registry

ple of the first	Var marine Arms		A STATE OF THE STA				
SLCTR regist	ts of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery +						
Scientific title of trial: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only							
Date of com	mencement (enrolr	ial: A Phase III, Open-label, Randomized, Multi-center Study of the te Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + urgery + Concurrent Chemoradiotherapy) in Subjects with Advanced at Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of the Oral Cavity / Soft Palate Versus Standard of Soft Palate Versus S					
Progression:	6 months □	1 year □	2 years □	3 years □			
	5 years √	6 years 🛚	At completion				
1. Baseline	edata		all room				
Any changes	to the trial design	/ methodology/ prot	ocol after commence	ment: None			
	s to trial outcomes dated 27 June 2014		t: Yes. Protocol amer	ndment 03			
2. Current	status	A STATE OF THE STA	The state of the s	.m			
	status: pending/ recruitment termin		ent complete/ recrui	tment			
Number asse	essed for eligibility:	97		us Standard of Care (Surgery + apy) in Subjects with Advanced Soft Palate Versus Standard of 17/Dec/2014 2 years			
Number recr	uited and allocated	l/randomized: 46					
Number alloc	cated/randomized t	to each intervention/	arm (please edit as r	elevant):			
Group	A:20	the state of the s	the state of the s	and the second of			
Group	ъ В:7			at Millian of the Millian			
Group	o C:19			A Charles			
osses/exclu	sions after allocation	on/randomization (p	ease edit as relevant):			
Group) A:4						
Group	B:1		A Walley Land				
Group	C:5						
The state of the s			and the same of th				

3. Trial output

Date of trial completion ("last patient, last visit"): 29 Nov 2019

Final sample size: 46

Summary of Interim/Final data (if available):

N/A	16 N	
N/A		

Abstract presentations of results at scientific meetings Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).	
N/A	N/A	
N/A	N/A	

Publications

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)		
N/A	N/A		
N/A	N/A		

Dr Prasad Abeysinghe

Co-ordinating Principal Investigator

Date:

18 November 2020